Viral Vectors & Plasmid DNA Manufacturing Market
Visiongain has published a new report entitled Viral Vectors & Plasmid DNA Manufacturing Market Report 2025-2035. This critical study estimates the Viral Vectors and Plasmid DNA manufacturing market at US$6.99 billion in 2025, projecting a CAGR of 15.9% during a ten-year forecast period to 2035.
Impact of the U.S. Trade Tariffs on the Global Viral Vectors and Plasmid DNA Manufacturing Market
The imposition of U.S. trade tariffs, particularly on key raw materials, bioprocessing equipment, and reagents imported from countries like China and the European Union, has disrupted the cost structures in the global viral vectors and plasmid DNA manufacturing market. These tariffs increase production costs for U.S.-based manufacturers who rely heavily on global supply chains for specialised inputs like single-use bioreactors, cell culture media, and DNA synthesis enzymes. In turn, this affects the pricing and competitiveness of U.S. companies in the international market. Many smaller biotech firms and contract development and manufacturing organisations (CDMOs) have been particularly impacted, as they operate with tighter margins and limited inventory buffers, reducing their ability to absorb additional costs.
Globally, these trade restrictions have prompted a strategic re-evaluation of supply chains. Some international manufacturers have shifted their operations or sourcing strategies to avoid U.S. tariffs, leading to increased investments in alternative manufacturing hubs in regions such as Southeast Asia and Eastern Europe. This redistribution of manufacturing capacities may accelerate the diversification of the viral vectors and plasmid DNA production landscape, potentially reducing the dominance of U.S.-based suppliers over time. Moreover, tariffs have heightened concerns about supply chain security and reliability, prompting companies to localise production where possible or pursue long-term partnerships to mitigate geopolitical risks.
The Growing Role of Plasmid DNA and Viral Vectors in Regenerative Medicine and Gene Therapy
Viral vectors are revolutionising gene therapy by enabling the direct delivery of therapeutic genes to targeted cells, addressing the root cause of many genetic disorders rather than just managing symptoms. On January 30, 2024, the American Society of Gene & Cell Therapy reaffirmed the critical role of viral vectors in achieving precision treatment through cell-specific gene delivery. This targeted approach boosts therapeutic effectiveness while minimising unwanted side effects seen with more generalised treatments. As innovation continues in viral vector design and gene delivery systems, the gene therapy landscape is expected to grow significantly, driven by better outcomes and broader therapeutic possibilities.
How will this Report Benefit you?
Visiongain’s 493-page report provides 213 tables and 278 charts/graphs. Our new study is aimed at anyone requiring commercial, in-depth analysis of the vaccine contract manufacturing market and detailed segment analysis. We predict strong opportunities in this fast-growing market from our evaluation of the global and regional landscape and market demand for viral vectors and plasmid DNA manufacturing. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise your overall productivity.
What are the Current Market Drivers?
Innovations in Manufacturing Processes
Ongoing advancements in the manufacturing of plasmid DNA as well as viral vectors are playing a pivotal role in driving the market growth. Breakthroughs focused on enhancing efficiency, scalability, and cost-effectiveness are helping manufacturers keep up with the rising demand for viral vector-based gene and cell therapies. For instance, on May 6, 2024, Takara Bio launched the Lenti-X Transduction Sponge, the world’s first dissolvable microfluidic enhancer created to boost the efficiency of transduction processes. This innovative solution revolutionises lentivirus-mediated gene delivery by improving efficiency and allowing for faster, smoother viral vector production. By optimising the transduction process, manufacturers can enhance the overall yield and quality of viral vectors, which is essential as gene therapy applications continue to expand. This advancement provides a valuable opportunity for manufacturers to streamline their production processes and remain competitive in the rapidly evolving viral vector market.
Recent Breakthroughs in Biotechnology Are Propelling Market Growth
Recent breakthroughs in biotechnology are transforming the healthcare landscape, with precision medicine and advanced therapies leading the charge. These personalised treatments, designed around an individual’s genetic profile, require highly accurate delivery systems to correct faulty genes, suppress harmful pathways, or introduce therapeutic proteins. In this context, viral vectors and plasmid DNA play a pivotal role as effective and safe carriers for delivering genetic material directly to targeted cells. Advances in gene editing technologies such as CRISPR-Cas9, base editing, and epigenetic reprogramming have significantly expanded the scope of treatable conditions through gene and cell therapy. As a result, there is a growing need for dependable, scalable manufacturing of viral vectors and plasmid DNA to support this next generation of precision treatments.
Where are the Market Opportunities?
Increasing Strategic Initiatives Among Market Players Are Driving Growth in the Viral Vector and Plasmid DNA Market
The viral vectors and plasmid DNA market is experiencing robust growth, fuelled by a surge in strategic initiatives such as facility expansions and collaborative partnerships. Companies are increasingly investing in advanced infrastructure to meet rising global demand for gene therapies, cell-based therapies, and DNA-based vaccines. For instance, FUJIFILM Diosynth Biotechnologies opened a state-of-the-art manufacturing facility in Denmark on January 9, 2025, significantly boosting production capabilities for viral vectors and other biologics in Europe. This expansion enhances regional manufacturing resilience and reduces reliance on overseas supply chains, which is especially critical in post-pandemic biomanufacturing strategies.
Novartis inaugurated its first dedicated viral vector facility in Slovenia on February 5, 2025, further underscoring the company’s commitment to scaling up its gene therapy operations within Europe. This move not only supports Novartis’ internal pipeline but also enhances its potential as a contract manufacturer for other biotech firms. Complementing these expansions, partnerships also play a crucial role in accelerating market growth. On February 4, 2025, Eleva and 3P Biopharmaceuticals formed a strategic GMP manufacturing alliance to increase capacity for Eleva’s unique expression platform. Such collaborations strengthen innovation pipelines and ensure more efficient and scalable production processes, collectively advancing the global availability of gene-based therapeutics.
Competitive Landscape
The major players operating in the vaccine contract manufacturing market are Advanced BioScience Laboratories Inc., Addgene, 3PBIOVIAN, Altogen Biosystems, Aldevron, BioNTech SE, Batavia Biosciences B.V., Amicus Therapeutics, ATUM, bluebird bio Inc., Boehringer Ingelheim, Catalent Inc., Waisman Biomanufacturing, Charles River Laboratories, SK pharmteco, Thermo Fisher Scientific Inc., Cytiva, Creative Biogene, RegenxBio Inc, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Merck KGaA, Genezen, Novartis, Lonza Group Ltd., Recipharm AB, Virovek, VIVEbiotech, VGXI, Inc., and Wuxi AppTec. These major players operating in the viral vectors and plasmid DNA market have adopted a range of strategies including mergers and acquisitions (M&A), strategic collaborations, increased investment in research and development (R&D), regional business expansions, partnerships, and the launch of new products to strengthen their market position and drive growth.
Recent Developments
On February 26, 2025, Aldevron collaborated with InDevR to evaluate a chip-based technology for assessing capping efficiency.
Notes for Editors
The in-depth study includes The Impact of U.S. Trade Tariffs, Forecasts by Type (Viral Vectors (Adeno-Associated Viruses (AAVs), Lentiviruses, Adenoviruses, Retroviruses, Others), Plasmid DNA), by Product and Service (Products, Services), by Workflow (Downstream Manufacturing (Purification, Fill Finish), Upstream Manufacturing (Vector Amplification and Expansion, Vector Recovery/Harvesting), by Application (Vaccine Development, Cell Therapy, Gene Therapy, Antisense & RNAi Therapy, Others), by Indication (Cancer, Infectious Diseases, Genetic Disorders, Others), by End-users (Biotechnology and Biopharmaceutical Companies, CDMOs, Academics and Research Institutes, Others) AND Regional and Leading National Market Analysis, PLUS Analysis of Leading Companies.
If you would like a more detailed overview of this report, please email contactus@visiongain.com or call +44 207 336 6100.
About Visiongain
Visiongain is a leading media company in Europe. Headquartered in London, UK, Visiongain specialises in producing a wide range of business-to-business reports covering key industries such as automotive, aviation, chemicals, cybersecurity, defence, energy, food & beverage, materials, packaging, pharmaceuticals, and utilities. Over the past 25 years, Visiongain has established itself as a trusted resource for business professionals seeking independent, high-quality, original insights to support their decision-making.
